BACKGROUND: Although clinicians avoid giving meropenem to patients with penicillin allergy because of potential cross-reactivity, the rate of cross-reactivity between penicillins and meropenem has not been prospectively determined. OBJECTIVE: To assess the tolerability of meropenem in patients with documented penicillin allergy. DESIGN: Prospective skin testing and antibiotic challenge. SETTING: Allergy units of 2 Italian medical centers. PATIENTS: 104 consecutive participants with immediate hypersensitivity reactions to penicillins and positive skin test results to at least 1 penicillin reagent. MEASUREMENTS: Skin tests to meropenem and, if results were negative, challenges with escalating doses of meropenem. RESULTS: One participant (0.9% [95% CI, 0.02% to 5.2%]) had a positive intradermal test result to meropenem. The remaining 103 participants with negative skin test results to meropenem tolerated escalating dose challenges. LIMITATION: Challenges were not followed by therapeutic courses. CONCLUSIONS: These data indicate a low rate of cross-reactivity between penicillins and meropenem. Therefore, the practice of avoiding meropenem therapy in penicillin-allergic patients should be reconsidered. In patients who especially require meropenem treatment, the authors recommend pretreatment skin tests because negative results indicate tolerability.
BACKGROUND: Although clinicians avoid giving meropenem to patients with penicillinallergy because of potential cross-reactivity, the rate of cross-reactivity between penicillins and meropenem has not been prospectively determined. OBJECTIVE: To assess the tolerability of meropenem in patients with documented penicillinallergy. DESIGN: Prospective skin testing and antibiotic challenge. SETTING:Allergy units of 2 Italian medical centers. PATIENTS: 104 consecutive participants with immediate hypersensitivity reactions to penicillins and positive skin test results to at least 1 penicillin reagent. MEASUREMENTS: Skin tests to meropenem and, if results were negative, challenges with escalating doses of meropenem. RESULTS: One participant (0.9% [95% CI, 0.02% to 5.2%]) had a positive intradermal test result to meropenem. The remaining 103 participants with negative skin test results to meropenem tolerated escalating dose challenges. LIMITATION: Challenges were not followed by therapeutic courses. CONCLUSIONS: These data indicate a low rate of cross-reactivity between penicillins and meropenem. Therefore, the practice of avoiding meropenem therapy in penicillin-allergicpatients should be reconsidered. In patients who especially require meropenem treatment, the authors recommend pretreatment skin tests because negative results indicate tolerability.
Authors: Jason A Trubiano; Cosby A Stone; M Lindsay Grayson; Karen Urbancic; Monica A Slavin; Karin A Thursky; Elizabeth J Phillips Journal: J Allergy Clin Immunol Pract Date: 2017-08-23
Authors: Kimberly G Blumenthal; Erica S Shenoy; Shelley Hurwitz; Christy A Varughese; David C Hooper; Aleena Banerji Journal: J Allergy Clin Immunol Pract Date: 2014-04-24
Authors: So Hee Lee; Heung Woo Park; Sae Hoon Kim; Yoon Seok Chang; Sun Sin Kim; Sang Heon Cho; Kyung Up Min; You Young Kim Journal: Korean J Intern Med Date: 2010-06-01 Impact factor: 3.165
Authors: Faisal A Khasawneh; Megan A R Slaton; Stephen L Katzen; Ashley A Woolbert; Sean D Anderson; Michelle B Parker; Rachel M Anderson; Krystal K Haase; Roger D Smalligan Journal: Int J Gen Med Date: 2013-12-06